From clearer diagnoses to faster matching for clinical trials: How Singapore’s precision medicine sector is changing patient care
The Straits Times article The Straits Times video
Media Coverage
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
Madrigal Pharmaceuticals Press Release
Singapore: A Myriad of Biotech Financing Strategies
Precision diagnostics firm Histoindex began life as a spinoff from A*STAR and so received funding from the Singaporean government as well as from angel investors, corporations, and institutions. Co-founder and CEO, Dr. Gideon Ho, highlights Singapore’s advantages for innovative start-up firms looking to grow in Singapore.
Singapore: A Myriad of Biotech Financing Strategies Read More »
A proprietary biophotonics technology and platform for stain-free AI-based digital pathology
Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue analysis focused on the diagnosis of fibrosis and cancer, and his thoughts on the Singaporean healthcare start-up ecosystem.
Behind the Success of Singapore’s Healthcare and Biomedical Startups
Singapore has always been regarded as a hotspot for startup growth and innovation.
Behind the Success of Singapore’s Healthcare and Biomedical Startups Read More »